Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc reports that, on 28 November 2025, it repurchased 250,000 ordinary shares of 31¼ pence each through BNP Paribas SA as part of its existing share buyback programme. The shares were bought at prices between 1,786.00p and 1,809.50p per share, with a volume‑weighted average price of 1,799.00p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 11,143,733 ordinary shares under this programme. After these latest purchases, GSK holds 236,608,577 shares in treasury and has 4,078,825,107 ordinary shares in issue, giving a total of 4,078,825,107 voting rights. GSK states that treasury shares represent 5.80% of its voting rights, a figure shareholders can use when determining notification obligations under UK disclosure rules.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 245,000 ordinary shares of 31¼ pence each on 27 November 2025 as part of its existing share buyback programme. The shares were bought at prices between 1,795.50p and 1,812.00p per share, with a volume‑weighted average price of 1,804.14p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought back 10,893,733 ordinary shares. After this latest transaction, it holds 236,358,577 shares in treasury and has 4,079,073,350 ordinary shares in issue, which is also the total number of voting rights. GSK states that treasury shares now represent 5.79% of voting rights, a figure investors can use for ownership and disclosure calculations.
GSK plc reports that it bought back 170,733 of its ordinary shares on 26 November 2025 through BNP Paribas SA, at prices between 1,794.50p and 1,819.50p per share, with a volume-weighted average price of 1,807.55p. These shares will be held as treasury shares as part of the company’s existing buyback programme, which has repurchased 10,648,733 shares since 30 September 2025.
After this transaction, GSK holds 236,113,577 shares in treasury and has 4,079,318,350 ordinary shares in issue, which is also the total number of voting rights in the company. GSK confirms that treasury shares now represent 5.79% of the voting rights, a figure shareholders can use when assessing disclosure thresholds under UK transparency rules.
GSK plc reports that on 17 November 2025 it repurchased 170,000 ordinary shares of 31¼ pence each through BNP Paribas SA under its existing buyback programme. The shares were bought at prices between 1,781.00p and 1,800.50p per share, with a volume-weighted average price of 1,789.39p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 9,170,000 ordinary shares under this programme. After this transaction, it holds 256,634,844 shares in treasury and has 4,058,796,266 ordinary shares in issue, which is also the total number of voting rights. The percentage of voting rights represented by treasury shares is stated as 6.32%.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 170,000 ordinary shares of 31¼ pence each on 14 November 2025 as part of its existing share buyback programme, at a volume-weighted average price of 1,788.23p per share, with prices ranging from 1,777.00p to 1,807.50p.
The repurchased shares will be held as treasury shares. Since 30 September 2025, the company has bought back a total of 9,000,000 ordinary shares under this programme.
After this transaction, GSK holds 256,464,844 shares in treasury and has 4,058,966,266 ordinary shares in issue, which is also the total number of voting rights. Treasury shares represent 6.32% of the voting rights attributable to ordinary shares.
GSK plc reported a routine share buyback transaction. Acting through BNP Paribas SA, the company purchased 167,000 ordinary shares on 13 November 2025 as part of its existing programme. Prices ranged from 1,794.50p to 1,817.50p with a volume‑weighted average price of 1,806.51p. The shares will be held as Treasury shares.
Since 30 September 2025, GSK has purchased 8,830,000 ordinary shares under the programme. After this purchase, GSK holds 256,294,844 shares in treasury and has 4,059,133,530 ordinary shares in issue (excluding treasury). Total voting rights are 4,059,133,530, and treasury-held voting rights represent 6.31%.
GSK plc reported routine insider share acquisitions by multiple senior executives under its Share Reward Plan. The transactions covered Ordinary Shares of 31 ¼ pence each (ISIN: GB00BN7SWP63) at £18.1420 per share on the London Stock Exchange.
Participants included CEO Emma Walmsley and CFO Julie Brown, each acquiring 14 Ordinary Shares (7 partnership and 7 matching). Other executives—James Ford, Sally Jackson, Regis Simard, Philip Thomson, and Victoria Whyte—also acquired 14 shares each on 2025-11-11. David Redfern acquired 12 shares (6 partnership and 6 matching). These are standard plan-related purchases disclosed via Form 6-K.
GSK plc reported a buyback transaction executed via BNP Paribas SA on 12 November 2025, purchasing 167,000 ordinary shares at a volume‑weighted average price of 1,813.49p (range 1,805.50p–1,827.00p). The shares will be held as treasury shares and form part of the company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 8,663,000 shares. Following this transaction, GSK holds 256,127,844 shares in treasury and has 4,059,300,530 shares in issue (excluding treasury). The total number of voting rights is 4,059,300,530, and the percentage of voting rights attributable to treasury shares is 6.31%.
GSK plc filed a Form 6‑K reporting its UK block listing six‑monthly return for the period from 1 May 2025 to 31 October 2025, detailing movements under three employee share plans.
Under the GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan, securities issued/allotted were 0, with a balance of unallotted securities of 115,518 at period end.
For the GlaxoSmithKline plc Share Save Plan 2012, securities issued/allotted were 134,547, leaving a balance of unallotted securities of 135,768 at period end.
For the GlaxoSmithKline plc Share Save Plan 2022, securities issued/allotted were 47,674, with a balance of unallotted securities of 904,117 at period end.
GSK plc reported share repurchases under its ongoing buyback. On 11 November 2025, the company bought 167,000 ordinary shares at prices between 1,791.50p and 1,825.00p, with a volume‑weighted average price of 1,807.35p. The shares will be held as treasury shares and the purchases were executed by BNP Paribas SA under a non‑discretionary agreement announced on 30 September 2025. Since that date, GSK has purchased 8,496,000 shares.
Following these transactions, GSK holds 255,960,844 shares in treasury and has 4,059,467,530 shares in issue (excluding treasury shares). The total number of voting rights is 4,059,467,530, and the percentage of voting rights attributable to treasury shares is 6.31%.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
